Tag: Sygnature Discovery

June 3, 2020 Off

Sygnature expands capabilities with acquisition of Alderley Oncology

By Dino Mustafić

Sygnature Discovery, a leading independent integrated drug discovery and pre-clinical services company, is further strengthening its oncology and immuno-oncology capabilities with the acquisition of Alderley Oncology, a focused in vivo pharmacology service provider which undertakes high quality in vivo services for biotechs, pharmaceutical companies and academics.